Mecamylamine - Vyera Pharmaceuticals

Drug Profile

Mecamylamine - Vyera Pharmaceuticals

Alternative Names: Mecamine-hydrochloride; Mecamylamine-hydrochloride; Vecamyl

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Retrophin
  • Developer Vyera Pharmaceuticals
  • Class Eye disorder therapies; Norbornanes; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Autistic disorder

Most Recent Events

  • 01 Sep 2017 Turing Pharmaceuticals is now called Vyera Pharmaceuticals (Vyera Pharmaceuticals California Comprehensive Compliance Program, September 2017)
  • 24 Feb 2015 Turing Pharmaceuticals acquires Vecamyl® from Retrophin
  • 24 Feb 2015 Early research in Autistic disorder in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top